Bragar Eagel & Squire, P.C. Is Investigating BeiGene and Fox and Encourages Investors to Contact the Firm
10 juil. 2023 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims BeiGene, Ltd. (NASDAQ: BGNE) and...
Bragar Eagel & Squire, P.C. Is Investigating Fox and BeiGene and Encourages Investors to Contact the Firm
05 juil. 2023 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corp. (NASDAQ: FOX,...
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
25 juin 2023 16h00 HE
|
The Rosen Law Firm PA
WHY: NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene,...
BGNE INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
17 juin 2023 16h21 HE
|
The Rosen Law Firm PA
NEW YORK, June 17, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene,...
BeiGene Reports Second Quarter 2020 Financial Results
06 août 2020 16h05 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Aug. 06, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress
05 août 2020 07h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China
17 juil. 2020 09h00 HE
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering
15 juil. 2020 17h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, July 15, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering
12 juil. 2020 20h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, July 12, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research
02 juil. 2020 07h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, July 02, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...